.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Teva
Accenture
Express Scripts
Cipla
Mallinckrodt
Dow
Daiichi Sankyo
Citi
Harvard Business School

Generated: June 25, 2017

DrugPatentWatch Database Preview

Esmolol hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for esmolol hydrochloride and what is the scope of esmolol hydrochloride freedom to operate?

Esmolol hydrochloride
is the generic ingredient in six branded drugs marketed by Hq Spclt Pharma, Aurobindo Pharma Ltd, West-ward Pharms Int, Luitpold Pharms Inc, Fresenius Kabi Usa, Mylan Institutional, and Baxter Hlthcare, and is included in seven NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Esmolol hydrochloride has forty patent family members in twenty-five countries.

There are eight drug master file entries for esmolol hydrochloride. Ten suppliers are listed for this compound.

Summary for Generic Name: esmolol hydrochloride

Tradenames:6
Patents:7
Applicants:7
NDAs:7
Drug Master File Entries: see list8
Suppliers / Packagers: see list10
Bulk Api Vendors: see list49
Clinical Trials: see list2,301
Patent Applications: see list812
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:esmolol hydrochloride at DailyMed

Pharmacology for Ingredient: esmolol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-006Feb 25, 2003APRXYesYes6,528,540*PED► SubscribeY► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-007May 28, 2003DISCNNoNo6,528,540*PED► SubscribeY► Subscribe
Luitpold Pharms Inc
ESMOLOL HYDROCHLORIDE
esmolol hydrochloride
INJECTABLE;INJECTION201126-001Feb 20, 2015APRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
ESMOLOL HYDROCHLORIDE
esmolol hydrochloride
INJECTABLE;INJECTION205520-001Jul 23, 2015APRXNoNo► Subscribe► Subscribe
Hq Spclt Pharma
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
esmolol hydrochloride
SOLUTION;INTRAVENOUS205703-001Apr 7, 2016RXYesYes6,528,540► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: esmolol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-006Feb 25, 20034,593,119*PED► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-007May 28, 20034,593,119*PED► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 19884,387,103► Subscribe
Baxter Hlthcare
BREVIBLOC IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-004Feb 16, 20014,593,119*PED► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 19885,017,609*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: esmolol hydrochloride

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)02076446► Subscribe
Hungary0204520► Subscribe
Australia2002309475► Subscribe
Spain2272720► Subscribe
Canada2410446► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Novartis
US Department of Justice
Argus Health
Colorcon
Federal Trade Commission
Baxter
QuintilesIMS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot